Navigation Links
PET/CT bests gold standard bone marrow biopsy for diagnosis and prognosis of lymphoma patients
Date:8/1/2013

Reston, Va. A more precise method for determining bone marrow involvement in patients with diffuse large B-cell lymphoma (DLBCL)a key factor in tailoring patient management planshas been identified by researchers in a study published in the August issue of The Journal of Nuclear Medicine. Imaging with 18F-FDG positron emission tomography/computed tomography (PET/CT), when compared to bone marrow biopsy, was more sensitive, showed a higher negative predictive value and was more accurate, changing treatment for 42 percent of patients with bone marrow involvement.

DLBCL is the most frequent subtype of high-grade non-Hodgkin lymphoma, accounting for nearly 30 percent of all newly diagnosed cases in the United States. In recent decades, there has been a 150 percent increase in incidence of DLBCL.

"In our study, we showed that in diffuse large B-cell lymphoma, 18F-FDG PET/CT has better diagnostic performance than bone marrow biopsy to detect bone marrow involvement and provides a better prognostic stratification. While bone marrow biopsy is considered the gold standard to evaluate bone marrow involvement by high-grade lymphomas, 18F-FDG PET/CT is in fact the best method to evaluate extension of the disease, as well as avoid invasive procedures," said Louis Berthet, MD, lead author of the study "In Newly Diagnosed Diffuse Large B-Cell Lymphoma, Determination of Bone Marrow Involvement with 18F-FDG PET/CT Provides Better Diagnostic Performance and Prognostic Stratification Than Dose Biopsy."

The retrospective study included 133 patients diagnosed with DLBCL. All patients received both a whole-body 18F-FDG PET/CT scan, as well as a bone marrow biopsy to determine bone marrow involvement. A final diagnosis of bone marrow involvement was made if the biopsy was positive, or if the positive PET/CT scan was confirmed by a guided biopsy, by targeted magnetic resonance imaging (MRI) or, after chemotherapy, by the concomitant disappearance of focal bone marrow uptake and uptake in other lymphoma lesions on 18F-FDG PET/CT reassessment. Progression-free survival and overall survival were then analyzed.

Thirty-three patients were considered to have bone marrow involvement. Of these, eight were positive according to the biopsy and 32 were positive according to the PET/CT scan.18FDG PET/CT was more sensitive (94 percent vs. 24 percent), showed a higher negative predictive value (98 percent vs. 80 percent) and was more accurate (98 percent vs. 81 percent) than bone marrow biopsy. Among the 26 patients with positive 18F-FDG PET/CT results and negative biopsy results, 11 were upstaged to stage IV by PET/CT, which changed their treatment plans. 18F-FDG PET/CT was also determined to be an independent predictor of progression-free survival.

"Our findings add to the literature to prove the significance of 18F-FDG PET/CT in cancer evaluation and to democratize this imaging method," said Berthet. "Molecular imaging is the best method to adapt targeted therapies to each patient. The emergence of PET/MRI and novel radiotracers predicts an exciting new future for our field.


'/>"/>

Contact: Susan Martonik
smartonik@snmmi.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Study examines necessity of additional imaging in PET/CT oncologic reports
2. Benefit of PET and PET/CT in ovarian cancer is not proven
3. Pretreatment PET/CT imaging of lymph nodes predicts recurrence in breast cancer patients
4. Benefit of PET or PET/CT in recurrent bowel cancer is not proven
5. PET/CT shows clear advantages over conventional staging for breast cancer patients
6. Inflammatory bowel disease detection enhanced with PET/CT
7. Heart: Cardiac PET/MR measures up to PET/CT
8. U.S. Bests Canada, Europe in Drug Approvals
9. Bestselling Author Hellen Chen Talked About the Pitfalls of Dating and What is Causing Marriages to Fail in Recent Workshops
10. Holistic Family Doctor Authors Amazon Bestselling Book in Response to ObamaCare
11. NY Times Bestselling Author Dr. Eben Alexander to Speak at Sofia University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... 12, 2016 , ... Fisher House Foundation Chairman and CEO Kenneth Fisher joined ... Support Alliance president Scott Bensing, and Peggy Kearns Director, VA Southern Nevada Healthcare System ... This will be the first Fisher House in Nevada, and will provide free ...
(Date:2/12/2016)... ... 12, 2016 , ... Erlanger Agency has announced a new partnership in its ... campaign focuses on the fight against breast cancer, fundraising for a local woman named ... . , Carmen is a loving single mother of two boys who also serves ...
(Date:2/12/2016)... Lakeland, FL (PRWEB) , ... February 12, 2016 , ... ... Coast Dental hygienist Suzan Sweeney, RDH, and dental assistant Terrell Moore shortly before 7 ... They joined dozens of dental professionals, donating their time and skills to help hundreds ...
(Date:2/12/2016)... ... February 12, 2016 , ... Atlantic Information ... Health Plans and PBMs,” an upcoming Feb. 24 webinar that will discuss ways ... big-dollar therapeutic categories, such as the $1,000-per-pill hepatitis C treatment Sovaldi and high-cost ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Healthcare careers in ... five most searched jobs via the website of healthcare staffing leader Aureus Medical Group ... travel nurse jobs , travel therapy positions and in travel and direct ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... , Feb. 11, 2016  Kindred Biosciences, Inc. (NASDAQ: ... and improving the lives of pets, today announced the ... the New Animal Drug Application (NADA) for Zimeta™ (dipyrone ... study (KB0120) of Zimeta for the control of pyrexia ... --> --> The ...
(Date:2/11/2016)... 11, 2016   Health 2.0 , the premiere ... technologies, announced today " 10 Year Global Retrospective ", ... over the past ten years.   ... Health 2.0 has served as the preeminent thought-leader in ... thousands of technologies, companies, innovators, and patient-activists through an ...
(Date:2/11/2016)... 2016  MiMedx Group, Inc. (NASDAQ: MDXG ), ... and other birth tissues, human skin and bone, and ... advanced products and therapies, announced today that it will ... Conference in New York , NY.  ... J. Senken , Chief Financial Officer and Chris ...
Breaking Medicine Technology: